{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'The following endpoints in the randomized set are also included in the secondary efficacy', 'endpoints:', 'OS', 'PFS per the CRAC based on RECIST v1.1', 'ORR per the CRAC based on RECIST v1.1', 'Secondary time-to-event endpoints (PFS and OS) will be analyzed using the similar', 'statistical methods described for the primary endpoints.', 'The duration of overall response for a given subject will be defined as the number of', 'months from the day the criteria are met for complete response (CR) or partial response', '(PR) by CRAC (whichever is recorded first) to the date of progressive disease or death,', 'whichever comes first. If a subject is still responding (i.e., has not progressed nor died', \"after CR or PR), then the subject's data will be censored at date of the last radiographic\", \"assessment by CRAC. For subjects who never experienced CR or PR, these subjects' data\", 'will not be included in the duration of response analysis. Distribution of the duration of', 'response will be estimated for each treatment arm using Kaplan-Meier methodology.', 'Median duration of overall response with corresponding 95% CI for each treatment arm', 'will be provided.', 'ORR and CBR in the treatment arm will be compared using Cochran-Mantel-Haensze', 'test stratified by randomization stratification factors. Rates and 95% confidence intervals', 'will be reported for each treatment arm.', 'Has been changed to read:', '8.1.5', 'Secondary Efficacy Endpoints', 'The secondary efficacy endpoints in the randomized set are:', 'os', '190']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'PFS per the CRAC based on RECIST v1.1', 'EORTC QLQ-C30 physical functioning domain', 'Secondary time-to-event endpoints (PFS and OS) will be analyzed using the similar', 'statistical methods described for the primary endpoints.', '8.1.6', 'Exploratory Efficacy Enppoints', 'The exploratory efficacy endpoints in both DLL3 high and randomization set are:', 'Objective response rate (ORR) per the CRAC based on RECIST v1.1', 'PFS per investigator assessment based on RECIST v1.1', 'ORR per investigator assessment based on RECIST v1.1', 'Clinical benefit rate (CBR) per the CRAC and investigator assessment,', 'respectively, based on RECIST v1.1', 'Duration of response (DOR) per CRAC and investigator assessment,', 'respectively', 'Change from baseline in all PRO domains (except physical functioning)', 'measured by EORTC QLQ-C30/LC13 and EQ-5D-5L', 'ORR is defined as the proportion of patients with a best overall response (BOR) of', 'confirmed complete response (CR) or partial response (PR) by CRAC review according to', 'RECIST v1.1.', 'CBR is defined as the proportion of patients with a BOR of CR or PR, or SD by CRAC', 'review according to RECIST v1.1.', 'ORR and CBR in treatment arms will be compared using Cochran-Mantel-Haensze test', 'stratified by randomization stratification factors. Rates and 95% confidence intervals will', 'be reported for each treatment arm.', 'The duration of overall response for a given subject will be defined as the number of', 'months from the day the criteria are met for confirmed complete response (CR) or partial', '191']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'response (PR) by CRAC (whichever is recorded first) to the date of progressive disease or', 'death, whichever comes first. If a subject is still responding (i.e., has not progressed nor', \"died after CR or PR), then the subject's data will be censored at date of the last\", 'radiographic assessment by CRAC. For subjects who never experienced CR or PR, these', \"subjects' data will not be included in the duration of response analysis. Distribution of the\", 'duration of response will be estimated for each treatment arm using Kaplan-Meier', 'methodology. Median duration of overall response with corresponding 95% CI for each', 'treatment arm will be provided.', 'Section 8.1.6 Patient Reported Outcomes (PRO)', 'First sentence previously read:', 'Physical functioning scale score in EORTC QLQ-C30 is the primary PRO endpoint.', 'Has been changed to read:', 'Physical functioning scale score in EORTC QLQ-C30 is the key secondary endpoint.', 'Section 8.1.7 Planned Sensitivity and Subgroup Analyses', 'Delete: first paragraph', 'Efficacy analyses for PFS per investigator assessment and ORR per investigator', 'assessment will be performed in the randomized set.', 'Section 8.1.7 Planned Sensitivity and Subgroup Analyses', 'Delete: third paragraph', 'The physical functioning scale score (EORTC QLQ-C30) will be evaluated using an', 'ANOVA model in the randomized set.', '192']\n\n###\n\n", "completion": "END"}